FDA
-
-
-
-
-
-
-
Edesa Biotech (EDSA) and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
-
-
-
-
-
-
-
Edesa Biotech Reports Fiscal Year 2022 Results
-
-
-
-
-
-
-
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
-
-
-
-
-
-
-
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
-
-
-
-
-
-
-
Edesa Biotech (EDSA) Reports First Patient Enrollment in Phase 2b Dermatitis Study
-
-
-
-
-
-
-
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
249,358 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All